SAT658 Tirzepatide Reduces The Predicted Risk Of Developing Atherosclerotic Cardiovascular Disease: A Post-hoc Analysis Of The Surmount-1 Trial

Disclosure: E.R. Hankosky: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. H. Wang: Other; Self; Eli Lilly & Company. N.M. Lisa: Employee; Self; Eli Lilly & Company. Stock Owner; Self; Eli Lilly & Company. H. Kan: Employee; Self; Eli Lilly & Compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hankosky, Emily R, Wang, Hui, Lisa, Neff M, Kan, Hongjun, Wang, Fangyu, Ahmad, Nadia N, Stefanski, Adam, Timothy Garvey, W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Adipose Tissue, Appetite, & Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554341/
http://dx.doi.org/10.1210/jendso/bvad114.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554341/
http://dx.doi.org/10.1210/jendso/bvad114.106

Ejemplares similares